Close Menu

NEW YORK — The US Food and Drug Administration on Wednesday granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by Beijing Wantai Biological Pharmacy.

According to the Beijing-based company, the test is designed to detect the N and ORF1ab genes of the virus in oropharyngeal swab specimens. Nucleic acid extraction is performed using the company's Wantai Nucleic Acid Extracting Reagent or Qiagen's QIAamp Viral RNA Mini Kit, and the test runs on Bio-Rad Laboratories' CFX-96 instrument or Thermo Fisher Scientific's Applied Biosystems 7500 RT-PCR System.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.